MedTrace Logo

Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma

NCT04805203 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2023-10-19

No results posted yet for this study

Summary

Among all MM patients included in the cohort at the time of diagnosis of SARS-CoV-2 infection, blood samples will be collected at inclusion, at time of the infection acute phase in the most severe cases (when admitted in intensive care units), and at recovery. The following immune function tests will be evaluated, gammaglobulin measurements, lymphocytes counts, B, T, and NK cells analyses by cytometry, including exhaustion analyses. In addition, T cell repertoire sequencing looking for SARS-CoV-2- specific T cells, and serologies, will be evaluated at recovery and 6 months after MM treatment re-initiation.

Conditions

Interventions

OTHER

blood sample analyses

maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery

Sponsors & Collaborators

  • Intergroupe Francophone du Myelome

    lead NETWORK

Principal Investigators

  • Hervé Avet Loiseau, PU-PH · Intergroupe Francophone du Myelome

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-16
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04805203 on ClinicalTrials.gov